A Phase I/IIa, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, and Pharmacokinetics of Single and Multiple Ascending Dose of RP3128 in HV and Effect on LAR to Allergen Challenge in Mild Asthmatics
Phase of Trial: Phase I/II
Latest Information Update: 27 Mar 2018
At a glance
- Drugs RP 3128 (Primary)
- Indications Asthma
- Focus Adverse reactions; Proof of concept
- Sponsors Rhizen Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 21 Mar 2018 Status changed from recruiting to discontinued.
- 01 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.